{"title":"卡斯特曼病患者的诊断难题--来自匈牙利的单中心经验。","authors":"Boglárka Brúgós,Zsófia Simon,Gábor Méhes,Árpád Illés,György Pfliegler","doi":"10.3389/pore.2024.1611785","DOIUrl":null,"url":null,"abstract":"Castleman disease is a rare and atypical lymphoproliferative disorder characterized by diverse clinical manifestations. It has both unicentric and multicentric forms, the latter with further subdivisions, i.e., human herpesvirus 8-associated and idiopathic forms. The diagnosis of Castleman disease is often delayed, as it is rare, and because it shares clinical features with different autoimmune, inflammatory, and malignant lymphoproliferative disorders. The first-line treatment in unicentric form is mainly surgical, while in idiopathic Castleman disease, anti-interleukin-6 treatment is the therapy of choice. In virus-associated diseases, antiretroviral therapy and rituximab are recommended. In Hungary, only a few cases of Castleman disease have been published. This report presents our two decades of experience in the challenging diagnosis and management of this rare disorder, most properly underdiagnosed in Hungary. We provide insights into seven unicentric and five idiopathic multicentric Castleman disease cases, the latter ones especially highlighting the diagnostic and therapeutic challenges due to the variable and unique clinical features both of patients and diseases, e.g., bronchiolitis obliterans, stage IV diabetic renal failure, anti-HBc positivity, siltuximab treatment period, respectively.","PeriodicalId":19734,"journal":{"name":"Pathology Oncology Research","volume":"57 1","pages":"1611785"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Diagnostic challenges in patients with Castleman disease, a single center experience from Hungary.\",\"authors\":\"Boglárka Brúgós,Zsófia Simon,Gábor Méhes,Árpád Illés,György Pfliegler\",\"doi\":\"10.3389/pore.2024.1611785\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Castleman disease is a rare and atypical lymphoproliferative disorder characterized by diverse clinical manifestations. It has both unicentric and multicentric forms, the latter with further subdivisions, i.e., human herpesvirus 8-associated and idiopathic forms. The diagnosis of Castleman disease is often delayed, as it is rare, and because it shares clinical features with different autoimmune, inflammatory, and malignant lymphoproliferative disorders. The first-line treatment in unicentric form is mainly surgical, while in idiopathic Castleman disease, anti-interleukin-6 treatment is the therapy of choice. In virus-associated diseases, antiretroviral therapy and rituximab are recommended. In Hungary, only a few cases of Castleman disease have been published. This report presents our two decades of experience in the challenging diagnosis and management of this rare disorder, most properly underdiagnosed in Hungary. We provide insights into seven unicentric and five idiopathic multicentric Castleman disease cases, the latter ones especially highlighting the diagnostic and therapeutic challenges due to the variable and unique clinical features both of patients and diseases, e.g., bronchiolitis obliterans, stage IV diabetic renal failure, anti-HBc positivity, siltuximab treatment period, respectively.\",\"PeriodicalId\":19734,\"journal\":{\"name\":\"Pathology Oncology Research\",\"volume\":\"57 1\",\"pages\":\"1611785\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pathology Oncology Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/pore.2024.1611785\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology Oncology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/pore.2024.1611785","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
卡斯特曼病是一种罕见的非典型淋巴组织增生性疾病,临床表现多种多样。它有单中心型和多中心型,后者又有进一步的细分,即人类疱疹病毒 8 相关型和特发性型。由于卡斯特曼病十分罕见,而且与不同的自身免疫性、炎症性和恶性淋巴细胞增生性疾病具有相同的临床特征,因此常常被延误诊断。单中心型的一线治疗主要是外科手术,而特发性卡斯特曼病的首选疗法是抗白细胞介素-6治疗。对于病毒相关性疾病,建议采用抗逆转录病毒疗法和利妥昔单抗。在匈牙利,只有少数几个卡斯特曼病病例发表过。本报告介绍了我们二十年来在诊断和治疗这种罕见疾病方面所积累的丰富经验。我们对七例单中心卡斯特曼病和五例特发性多中心卡斯特曼病病例进行了深入分析,其中特发性多中心卡斯特曼病病例尤其突出了诊断和治疗方面的挑战,因为患者和疾病的临床特征各不相同且各具特色,例如阻塞性支气管炎、糖尿病肾衰竭 IV 期、抗-HBc 阳性、硅妥昔单抗治疗期等。
Diagnostic challenges in patients with Castleman disease, a single center experience from Hungary.
Castleman disease is a rare and atypical lymphoproliferative disorder characterized by diverse clinical manifestations. It has both unicentric and multicentric forms, the latter with further subdivisions, i.e., human herpesvirus 8-associated and idiopathic forms. The diagnosis of Castleman disease is often delayed, as it is rare, and because it shares clinical features with different autoimmune, inflammatory, and malignant lymphoproliferative disorders. The first-line treatment in unicentric form is mainly surgical, while in idiopathic Castleman disease, anti-interleukin-6 treatment is the therapy of choice. In virus-associated diseases, antiretroviral therapy and rituximab are recommended. In Hungary, only a few cases of Castleman disease have been published. This report presents our two decades of experience in the challenging diagnosis and management of this rare disorder, most properly underdiagnosed in Hungary. We provide insights into seven unicentric and five idiopathic multicentric Castleman disease cases, the latter ones especially highlighting the diagnostic and therapeutic challenges due to the variable and unique clinical features both of patients and diseases, e.g., bronchiolitis obliterans, stage IV diabetic renal failure, anti-HBc positivity, siltuximab treatment period, respectively.